Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975-2016.
Surveillance, Epidemiology, and End Results (SEER)
adolescent and young adult
cancer
epidemiology
survival trends
survivorship
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 Nov 2021
15 Nov 2021
Historique:
revised:
10
06
2021
received:
03
03
2021
accepted:
22
06
2021
pubmed:
27
7
2021
medline:
11
3
2022
entrez:
26
7
2021
Statut:
ppublish
Résumé
Five-year relative survival for adolescent and young adult (AYA) patients with cancer diagnosed at the ages of 15 to 39 years is 85%. Survival rates vary considerably according to the cancer type. The purpose of this study was to analyze long-term survival trends for cancer types with the highest mortality among AYAs to determine where the greatest burden is and to identify areas for future research. Using data from the Surveillance, Epidemiology, and End Results cancer registry and the National Center for Health Statistics, the authors examined the incidence, mortality, and survival for the 9 cancer types with the highest mortality rates in this age group from 1975 to 2016. JPSurv, new survival trend software, was used in the analysis. Results suggested significant improvements in 5-year relative survival for brain and other nervous system tumors, colon and rectum cancer, lung and bronchus cancer, acute myeloid leukemia, and non-Hodgkin lymphoma (all P values < .05). Limited or no improvement in survival was found for female breast cancer, cervical cancer, ovarian cancer, and bone and joint sarcomas. Five-year relative survival for multiple cancer types in AYAs has improved, but some common cancer types in this group still show limited survival improvements (eg, ovarian cancer). Survival improvements in colorectal cancer have been overshadowed by its rising incidence, which suggests a substantial disease burden. Future research should focus on female breast, bone, ovarian, and cervical cancers, which have seen minimal or no improvements in survival. Survival trends for adolescents and young adults with cancer are presented from a 40-year period. Although survival progress is noted for brain cancer, lung cancer, acute myeloid leukemia, and colon and rectum cancer, the incidence of colon and rectum cancer remains high. Minimal progress is evident for female breast, bone, ovarian, and cervical cancers, which are in need of renewed focus.
Sections du résumé
BACKGROUND
BACKGROUND
Five-year relative survival for adolescent and young adult (AYA) patients with cancer diagnosed at the ages of 15 to 39 years is 85%. Survival rates vary considerably according to the cancer type. The purpose of this study was to analyze long-term survival trends for cancer types with the highest mortality among AYAs to determine where the greatest burden is and to identify areas for future research.
METHODS
METHODS
Using data from the Surveillance, Epidemiology, and End Results cancer registry and the National Center for Health Statistics, the authors examined the incidence, mortality, and survival for the 9 cancer types with the highest mortality rates in this age group from 1975 to 2016. JPSurv, new survival trend software, was used in the analysis.
RESULTS
RESULTS
Results suggested significant improvements in 5-year relative survival for brain and other nervous system tumors, colon and rectum cancer, lung and bronchus cancer, acute myeloid leukemia, and non-Hodgkin lymphoma (all P values < .05). Limited or no improvement in survival was found for female breast cancer, cervical cancer, ovarian cancer, and bone and joint sarcomas.
CONCLUSIONS
CONCLUSIONS
Five-year relative survival for multiple cancer types in AYAs has improved, but some common cancer types in this group still show limited survival improvements (eg, ovarian cancer). Survival improvements in colorectal cancer have been overshadowed by its rising incidence, which suggests a substantial disease burden. Future research should focus on female breast, bone, ovarian, and cervical cancers, which have seen minimal or no improvements in survival.
LAY SUMMARY
BACKGROUND
Survival trends for adolescents and young adults with cancer are presented from a 40-year period. Although survival progress is noted for brain cancer, lung cancer, acute myeloid leukemia, and colon and rectum cancer, the incidence of colon and rectum cancer remains high. Minimal progress is evident for female breast, bone, ovarian, and cervical cancers, which are in need of renewed focus.
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4277-4286Informations de copyright
© 2021 American Cancer Society. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
Références
Cancer Stat Facts: Cancer Among Adolescents and Young Adults (AYAs) (Ages 15-39). National Cancer Institute. Published 2020. Accessed August 11, 2020. https://seer.cancer.gov/statfacts/html/aya.html
Adolescent and Young Adult Oncology Progress Review Group. Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults With Cancer. US Department of Health and Human Services. Published 2006. Accessed July 19, 2021. https://www.cancer.gov/types/aya/research/ayao-august-2006.pdf
Smith AW, Seibel NL, Lewis DR, et al. Next steps for adolescent and young adult oncology workshop: an update on progress and recommendations for the future. Cancer. 2016;122:988-999.
Keegan THM, Ries L, Barr RD, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer. 2016;122:1009-1016.
Lewis DR, Seibel NL, Smith AW, Stedman MR. Adolescent and young adult cancer survival. J Natl Cancer Inst Monogr. 2014;49:228-235.
Moke DJ, Tsai K, Hamilton AS, et al. Emerging cancer survival trends, disparities, and priorities in adolescents and young adults: a California Cancer Registry-based study. JNCI Cancer Spectr. 2019;3:pkz031.
SEER*Stat Software. Version 8.3.9. National Cancer Institute. Published March 15, 2021. Accessed April 2021. https://seer.cancer.gov/seerstat/
Surveillance, Epidemiology, and End Results Program. SEER*Stat Database: Mortality-All COD, Aggregated Total U.S. (1990-2016) <Katrina/Rita Population Adjustment>. National Cancer Institute; 2018.
Surveillance, Epidemiology, and End Results Program. SEER*Stat Database: Incidence-SEER 21 Regs Limited-Field Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Sub (2000-2016), Katrina/Rita Population Adjustment>-Linked to County Attributes-Total U.S., 1969-2017 Counties. National Cancer Institute; 2019.
JPSurv analysis tool. National Cancer Institute. Accessed April 2021. https://analysistools.cancer.gov/jpsurv/
Mariotto AB, Zhang F, Buckman DW, Miller D, Cho H, Feuer EJ. How to characterize trends in cancer patient survival and an introduction to the JPSurv software. Cancer Epidemiol Biomarkers Prev. Forthcoming 2021.
Joinpoint trend analysis software. Version 3.5.1. National Cancer Institute. Accessed July 2019. https://surveillance.cancer.gov/joinpoint/
Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S. When do changes in cancer survival mean progress? The insight from population incidence and mortality. J Natl Cancer Inst Monogr. 2014;49:187-197.
Dickman PW, Adami H-O. Interpreting trends in cancer patient survival. J Intern Med. 2006;260:103-107.
Forjaz G, Chen H-S, Howlader N, Rego R, Rodrigues V, Mariotto AB. Measuring progress against cancer in the Azores, Portugal: incidence, survival, and mortality trends and projections to 2025. Cancer Epidemiol. 2020;69:101810. doi:10.1016/j.canep.2020.101810
Creutzig U, Zimmerman M, Reinhardt D, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122:3821-3830.
Tarlock K, Zhong S, He Y, et al. Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. Oncotarget. 2018;9:26417-26430.
Rowe JM. Will new agents impact survival in AML? Best Pract Res Clin Haematol. 2019;32:101094.
Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010.
Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694-701.
Creutzig U, Kutny MA, Barr R, Schlenk RF, Ribeiro RC. Acute myelogenous leukemia in adolescents and young adults. Pediatr Blood Cancer. 2018;65:e27089.
Howlader N Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2017. National Cancer Institute; 2020. https://seer.cancer.gov/csr/1975_2017/.
Fatemi P, Zhang M, Miller KJ, Robe P, Li G. How intraoperative tools and techniques have changed the approach to brain tumor surgery. Curr Oncol Rep. 2018;20:89.
Sack J, Steinberg JA, Rennert RC, et al. Initial experience using a high-definition 3-dimentional exoscope system for microneurosurgery. Oper Neurosurg (Hagerstown). 2018;14:395-401.
Scaringi C, Agolli L, Minniti G. Technical advances in radiation therapy for brain tumors. Anticancer Res. 2018;38:6041-6045.
Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2013;4:CD007415.
Zapotocky M, Ramaswamy V, Lassaletta A, Bouffet E. Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. Pediatr Blood Cancer. 2018;65:e26861.
Kamangar F, Dores G, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
Aberle DR, De Mello S, Berg CD, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013;369:920-931.
Wakelee H, Kelly K, Edelman MJ. 50 years of progress in the systemic therapy of non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2014:177-189.
Howlader N, Forjaz G, Mooradian M, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383:640-649.
Pierce JB, White MM, Messer K. Changing age-specific patterns of cigarette consumption in the United States, 1992-2002: association with smoke-free homes and state-level tobacco control activity. Nicotine Tob Res. 2009;11:171-177.
Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. Cancer. 2014;120:2883-2892.
Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109:djw322. doi:10.1093/jnci/djw322
Hidayat K, Yang CM, Shi BM. Body fatness at an early age and risk of colorectal cancer. Int J Cancer. 2018;142:729-740.
Tricoli JV, Boardman LA, Patidar R, et al. A mutational comparison of adult and adolescent and young adult (AYA) colon cancer. Cancer. 2018;124:1070-1082.
Howlader N, Shiels MS, Mariotto AB, Engels EA. Contributions of HIV to non-Hodgkin lymphoma mortality trends in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25:1289-1296.
Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645-1654.
Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer. 2017;123:3326-3334.
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
Plevritis SK, Munoz D, Kurian AW, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. JAMA. 2018;319:154-164.
Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systematic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014;106:dju289. doi:10.1093/jnci/dju289
Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001;92:2523-2528.
Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in young women: clinicopathological features and biological specificity. Breast. 2003;12:247-250.
Partridge AH, Hughes ME, Ottesen RA, et al. The effect of age on delay in diagnosis and stage of breast cancer. Oncologist. 2012;17:775-782.
Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003;97:134-147.
Freedman RA, Partridge AH. Management of breast cancer in very young women. Breast. 2013;22:S176-S179.
Link MP, Goorin A, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600-1606.
Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:4148-4154.
Nebgen DR, Lu KH, Bast RC. Novel approaches to ovarian cancer screening. Curr Oncol Rep. 2019;21:75. doi:10.1007/s11912-019-0816-0
Moller P, Seppala T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66:464-472.
Markowitz LE, Dunne EF, Saraiya M, et al. Human papilloma vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1-30.
Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702.
Drolet M, Benard E, Perez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394:497-509. doi:10.1016/S0140-6736(19)30298-3
Chao C, Xu L, Abrams D, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010;24:1765-1770.